This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Orlistat and effects on glycaemia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • orlistat is a lipase inhibitor that alters the absorption of fat through the gastrointestinal (GI) tract
    • results in the excretion of approximately 30% of ingested fat - thus reducing the calorie intake of the patient
    • studies have demonstrated that orlistat is clinically beneficial in reducing body weight and co-morbid risk factors in patients with Type 2 diabetes treated concomitantly with oral hypoglycaemic medications (1,2,3)
      • orlistat and effects on glycaemia
        • the XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study revealed that orlistat can also delay or prevent the development of Type 2 diabetes in high-risk patients (4)
        • use of orlistat in newly diagnosed type 2 diabetics not receiving oral hypoglycaemic agents
          • a study investigated evaluated the efficacy of 24 weeks’ treatment with orlistat, combined with a mildly reduced-calorie diet, on weight loss and glycaemic control in overweight and obese patients with newly diagnosed and previously untreated Type 2 diabetes (5)
            • study results revealed that orlistat-treated patients achieved a significantly greater decrease in fasting plasma glucose (-1.3 vs. -0.5 mmol/l; P = 0.0003) and in the 2-h oral glucose tolerance test (-4.1 vs. -1.4 mmol/l; P < 0.0001) than placebo recipients
            • a significant decrease in HbA1c from baseline was obtained with orlistat (-1.0 vs. -0.6%; P = 0.0008)
        • various studies have revealed the glycaemic benefits of using orlistat in patients with type 2 diabetes (1,2,3)
          • use of orlistat in patients already treated with maximal metformin and sulphonylyurea treatment (3) was investigated in a small study
            • total of 60 female type 2 diabetic patients with BMI > 25 kg/m2 and glycosylated haemoglobin (HbA1c) > 8% were assigned to two groups. In addition to their maximal doses of sulphonylureas (gliclazide (320 mg/day) or glipizide (20 mg/day)) and metformin (2000 mg/day), one group (n = 30) received a placebo and the other (n = 30) received orlistat (120 mg t.i.d.) for 12 weeks
              • study results revealed that mean fasting insulin levels decreased more in the orlistat group than in the placebo group (28.8 ± 3.0 vs. 2.4 ± 1.2 pmol/l; p < 0.01)
              • mean HbA1c values dropped by 1.7 ± 0.01% (p < 0.05) in the orlistat group, but remained unchanged in the placebo group
        • based on the glycaemic lowering effects of orlistat seen in studies, orlistat was classified as an oral hypoglycaemic agent in Canada in 2003 (6)

Reference:


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page